Time to disease progression drives outcomes after second-line BTKi therapy in relapsed or refractory MCLJuly 22, 2023B Cell Lymphoma
Commentary: New treatments for mantle cell lymphoma and B-cell lymphoma, July 2023June 29, 2023B Cell Lymphoma
Meta-analysis explores the best first-line immunotherapy regimens for transplant-ineligible MCLJune 20, 2023B Cell Lymphoma
Obinutuzumab+bendamustine a potent treatment option for relapsed or refractory CLLJune 20, 2023B Cell Lymphoma
Front-line BTK inhibitor+anti-CD20 antibody tops chemoimmunotherapy in CLL, reveals meta-analysisJune 20, 2023B Cell Lymphoma
R-High-CHOP/CHASER/LEED with auto-PBSCT provides favorable long-term survival outcomes in untreated MCLJune 20, 2023B Cell Lymphoma
Tafasitamab+lenalidomide provides survival benefit over pola-BR and R2 in relapsed or refractory DLBCLJune 20, 2023B Cell Lymphoma
First-line rituximab+bendamustine+cytarabine combination shows long-term efficacy in the elderly with MCLJune 20, 2023B Cell Lymphoma
First-line fixed-duration ibrutinib+venetoclax shows promise against high-risk CLLJune 20, 2023B Cell Lymphoma
Phase 3 data favor axi-cel over standard care in high-risk large B-cell lymphomaJune 20, 2023B Cell Lymphoma
Pirtobrutinib offers a promising treatment option for covalent BTK-inhibitor pretreated MCLJune 20, 2023B Cell Lymphoma
